Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.73 |
| ▸ | PI4KA | P42356 | 4/20 | 0.64 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.64 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.64 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.64 |
| ▸ | AHCY | P23526 | 5/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12620928 | 0.87 | ADORA2A (0.77) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL8815696 | 0.86 | ADORA2A (0.75) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL25861 | 0.86 | ADORA2A (0.75) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL17162883 | 0.84 | ADORA2A (0.73) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29135598 | 0.84 | ADORA2A (0.73) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29135599 | 0.84 | ADORA2A (0.73) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL17162884 | 0.84 | ADORA2A (0.73) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL904363 | 0.84 | ADORA2A (1.00) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL5810639 | 0.84 | ADORA2A (1.00) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29496348 | 0.84 | ADORA2A (1.00) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022379-A1 | Optimized RNAi Agents for Inhibiting Expression of Coronavirus (CoV) Viral Genomes, Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12486502-B2 | RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-2329830-A2 | Antisense inhibition of PTP1B expression | ISIS Pharmaceuticals, Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20050026182-A1 | Human CDNAS and proteins and uses thereof | SERONO GENETICS INSTITUTE S.A. (FR) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022379-A1 | Optimized RNAi Agents for Inhibiting Expression of Coronavirus (CoV) Viral Genomes, Compositions Thereof, and Methods of Use | SARS1, RBM26, METTL16 | ADORA2A 3263/4885ADORA1 2124/4885PI4KA 4677/4885 |
| US-12486502-B2 | RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use | AGER, ASGR1, TLR3 | ADORA2A 691/4885ADORA1 670/4885PI4KA 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.